Key result
This editorial emphasizes the urgent need for population-specific guidelines to manage cardiovascular disease risk and lipid abnormalities in HIV-infected children on antiretroviral therapy.
Why the study?
How do antiretroviral therapy and lipid-lowering interventions affect lipoprotein profiles and cardiovascular disease risk in HIV-infected children?
How do antiretroviral therapy and lipid-lowering interventions affect lipoprotein profiles and cardiovascular disease risk in HIV-infected children?
No takes yet. Share an insight, caveat, or question.
There is an urgent need for pediatric-specific guidelines to manage ART-associated dyslipidemia and chronic inflammation to mitigate long-term cardiovascular disease risk in HIV-infected children.
Ross et al. (2011) conducted an editorial in Pediatric HIV. Antiretroviral therapy and lipid-lowering management was evaluated. This editorial emphasizes the urgent need for population-specific guidelines to manage cardiovascular disease risk and lipid abnormalities in HIV-infected children on antiretroviral therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: